公开(公告)号：US20180327489A1

公开(公告)日：2018-11-15

申请号：US15973735

申请日：2018-05-08

Applicant: NOVARTIS AG

Inventor： Matthew John EDWARDS ,  Jean-Michel Rene RONDEAU ,  Danforth MILLER ,  Daniel HUANG ,  Hans-Peter KNOPF ,  Gino Anselmus VAN HEEKE ,  Rene HEMMIG ,  Kapil GUPTA ,  Nicole HAUBST ,  Barbara ANDLAUER

IPC: C07K16/24 ,  A61K9/00 ,  A61K9/16 ,  A61K39/395 ,  A61K45/06 ,  A61K39/00

Abstract: The invention provides molecules, e.g., antibodies or antibody fragments, that specifically bind thymic stromal lymphopoietin (TSLP), compositions comprising these molecules, and methods of using and producing these molecules.

公开(公告)号：US20210069106A1

公开(公告)日：2021-03-11

申请号：US16963678

申请日：2019-01-24

Applicant: Novartis AG

Inventor： Yoen-Ju SON ,  Daniel HUANG ,  Danforth MILLER ,  Jeffry G. WEERS

IPC: A61K9/00 ,  A61K9/16 ,  C07K16/24 ,  A61K31/5383 ,  A61K31/7036 ,  A61K31/137 ,  A61M15/00

Abstract: The present invention comprises methods and formulations to increase drug payload, especially in regard to a receptacle-based, inhalation dosed, dry powder therapeutic, wherein the methods and formulations are characterized by a high product density, as well as a high TLD per receptacle, while maintaining highly efficient aerosol performance from the device. Embodiments of the present invention comprise a spray-dried pharmaceutical powder comprising particles deliverable from a dry powder inhaler, the composition comprising active agent, and a shell-forming excipient, wherein the powder is characterized by a product density greater than 50 mg/ml.

公开(公告)号：US20200325218A1

公开(公告)日：2020-10-15

申请号：US16919020

申请日：2020-07-01

Applicant: NOVARTIS AG

Inventor： Barbara ANDLAUER ,  Matthew John EDWARDS ,  Kapil GUPTA ,  Nicole HAUBST ,  Rene HEMMIG ,  Daniel HUANG ,  Hans-Peter KNOPF ,  Danforth MILLER ,  Jean-Michel Rene RONDEAU ,  Gino Anselmus VAN HEEKE

IPC: C07K16/24 ,  A61K9/00 ,  A61K9/16 ,  A61P37/08 ,  A61P11/06 ,  A61K39/395 ,  A61K45/06

Abstract: The invention provides molecules, e.g., antibodies or antibody fragments, that specifically bind thymic stromal lymphopoietin (TSLP), compositions comprising these molecules, and methods of using and producing these molecules.